Baricitinib is a medication traditionally used in the management and treatment of Rheumatoid Arthritis. However, with the recent advent of the COVID-19 global pandemic, several agents have been evaluated for the management of this disease. Baricitinib is in the JAK inhibitor class of medications. This activity reviews the indications, action, and contraindications for the concurrent use of Remdesivir and Baricitinib as valuable agents in the management of COVID-19. This activity will highlight the mechanism of action, adverse event profile, and other key factors like indications and contraindications, dosing, pharmacodynamics, pharmacokinetics, pertinent for members of the interprofessional team in the management of patients with COVID-19 and related conditions
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/135904
- Start Date: 2023-09-01 05:00:00
- End Date: 2023-09-01 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.5 hours
Nursing: 1.5 hours
Pharmacy: 1.5 hours - MOC Credit Details: ABS - 1.5 Point; Credit Type(s): Accredited CME (ABS)
ABPATH - 1.5 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABA - 1.5 Point; Credit Type(s): Lifelong Learning (ABA)
ABIM - 1.5 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 1.5 Point; Credit Type(s): Self-Assessment (ABS)
ABP - 1.5 Point; Credit Type(s): Lifelong Learning and Self-Assessment (ABP)
ABIM - 1.5 Point; Credit Type(s): Patient Safety (ABIM)
ABA - 1.5 Point; Credit Type(s): Patient Safety (ABA) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: All Practice Areas (e.g. ethics), Critical Care Medicine, General Pediatrics, General Surgery, Hospital Medicine, Infectious Disease, Internal Medicine, Pediatric Critical Care Medicine